查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1714643

按药物类型、技术、治疗领域和最终用户分類的药物研发市场—2025-2030 年全球预测

Drug Discovery Market by Drug Type, Technology, Therapeutic Area, End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计2023年药物研发市场规模将达623.8亿美元，2024年将达711.2亿美元，年复合成长率为14.10%，到2030年将达到1571.3亿美元。

全面介绍药物发现的演变

主要市场统计数据
基准年2023年 623.8亿美元
预计2024年 711.2亿美元
预测年份 2030 1571.3亿美元
复合年增长率（%） 14.10%

近年来，药物研发领域已经超越了传统的研究典范。这一转变是由科学创新、先进技术以及不断变化的监管和市场环境共同推动的。相关人员努力加速从实验室突破到可行治疗解决方案的进程，业界利用多方面见解和尖端方法的努力比以往任何时候都更加重要。

计算生物学、实验通讯协定自动化和资料科学的整合的最新趋势正在重新定义早期药物开发的进行方式。各组织越来越多地投资于敏捷技术，这些技术不仅可以简化高通量筛检流程，还可以提高生物分析的准确性。这些努力使得药物发现生命週期更加互联、反应更快，其中迭代学习和快速原型製作正在成为常态。这样，该行业就可以满足日益增长的有效治疗方法需求，同时克服临床挑战。

此外，学术界、委外研发机构和大型製药企业之间的合作为该行业创造了合作基调。这种对多学科伙伴关係和跨职能研究的日益重视凸显了当今药物发现领域的变革议程，并为针对复杂疾病特征的创新治疗性介入奠定了基础。

重新定义药物研发格局的转捩点

药物研发领域正在经历变革，重新定义其基本运作架构。这种变化的主要驱动力是技术的快速进步，它将曾经繁琐的研究和开发週期转变为精简的、资料主导的流程。随着新技术不断融入传统研究工作流程，业界正见证科学严谨性与自动化和计算建模的无缝整合。

人工智慧、增强成像技术和强大的资料分析的进步不仅加速了先导化合物，而且提高了临床检验的准确性。这种转变与全球对个人化医疗的重视相辅相成，预计个人化医疗将带来更有效的治疗方法，解决患者群体的异质性。此外，不断发展的法律规范支援更快的核准流程，同时不影响安全性，从而培育出重视创新和敏捷性的生态系统。

这种动态培育了一种以合作为重的文化。研究机构、生物技术新兴企业和成熟製药公司正在汇集资源和专业知识来应对复杂的治疗挑战。技术和科学的广泛融合为药物发现的新时代奠定了基础，其中管理风险和投资尖端工具对于保持长期竞争优势至关重要。

关键的细分洞见将塑造未来的研究领域

仔细观察市场区隔就会发现，药物研发产业内存在许多层次的专业化。该行业根据药物类型进行细分，详细研究区分生物製药和小分子药物。这种区别对于开发平臺、监管途径和市场引入策略具有重要意义。

在技​​术方面，生物分析仪器、生物晶片、生物资讯等各种尖端工具已被引入并成为现代研究的支柱。组合化学、高通量筛检和奈米技术等先进技术也处于前沿，药物基因组学正在为个人化医疗和标靶治疗铺平道路。这些技术领域透过加速药物开发和确保治疗标靶的精准性而增加了巨大的价值。

根据治疗领域进一步细分，突显了药物发现工作的针对性应用。心血管疾病、消化器官系统、感染疾病和免疫疾病、神经病学和肿瘤学等重点关注领域代表了需要独特研究方法的多样化临床环境。最后，根据学术界、研究机构、委外研发机构和大型製药公司等最终用户进行细分，可以提供多层次的市场动态图景。以这种方式整合细分洞察，可使相关人员根据特定的市场需求和临床挑战调整策略，从而最大限度地提高研究收益和临床成功率。

目录

第一章 引言

第二章调查方法

第三章执行摘要

第四章 市场概述

第五章 市场洞察

  • 市场动态
    • 驱动程式
      • 製药和生物製药产业研发成本不断增加
      • 管理临床前研究期间产生的大量资料的需求日益增长
      • 政府对药物研发平台发展的积极支持
    • 限制因素
      • 药物研发需要大量资金
    • 机会
      • 新的企业合作拓展了药物研发能力
      • 药物研发的技术进步与创新
      • 利用人工智慧云创建简化、自动化的药物研发方法
    • 任务
      • 药物研发中使用动物的严格标准
  • 市场区隔分析
    • 药物类型：品牌学名药推动小分子药物的需求
    • 技术：扩大早期生物分析仪器和高通量筛检的使用
    • 治疗领域：肿瘤药物研发中对药物发现的需求日益增加
    • 最终用户：製药和生物技术公司越来越多地利用药物发现来开发新的和改良的药物
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社会
    • 技术的
    • 合法的
    • 环境

第六章 药物研发市场（依药物类型）

  • 生物製药
  • 小分子药物

第七章 药物研发市场（依技术）

  • 生物分析仪器
  • 生物晶片
  • 生物资讯学
  • 组合化学
  • 高通量筛检
  • 奈米科技
  • 药物基因组学

第八章 药物研发市场（依治疗领域）

  • 心血管疾病
  • 消化器官系统疾病
  • 感染疾病及免疫系统疾病
  • 神经病学
  • 肿瘤学

第九章 药物研发市场（依最终用户划分）

  • 学术和研究机构
  • 合约研究组织
  • 製药公司

第 10 章：美洲药物研发市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第 11 章：亚太药物研发市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第 12 章欧洲、中东和非洲的药物研发市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2023年市场占有率分析
  • 2023年FPNV定位矩阵
  • 竞争情境分析
  • 战略分析与建议

公司名单

  • Abbott Laboratories
  • Agilent Technologies, Inc.
  • Alacrita Holdings Limited
  • Alkem Laboratories Ltd
  • Amgen Inc.
  • Astex Pharmaceuticals by Otsuka Pharmaceutical Co., Ltd.
  • Astrazeneca PLC
  • Atomwise, Inc.
  • BenevolentAI
  • Bio-Rad Laboratories, Inc.
  • BioSymetrics Inc.
  • Charles River Laboratories International, Inc.
  • Chembridge Corporation
  • Cloud Pharmaceuticals, Inc.
  • Dalriada Drug Discovery
  • Deciphera Pharmaceuticals, Inc.
  • Eli Lilly and Company
  • Evotec SE
  • Exscientia PLC
  • F. Hoffmann-La Roche Ltd.
  • GENFIT SA
  • Incyte Corporation
  • International Business Machines Corporation
  • Intra-Cellular Therapies Inc.
  • Kvantify
  • Lantern Pharma Inc.
  • Merck KGaA
  • Microsoft Corporation
  • NVIDIA Corporation
  • PerkinElmer, Inc.
  • Pharmacelera SL
  • Piramal Group
  • Recursion Pharmaceuticals, Inc.
  • Sanofi SA
  • Schrodinger, Inc.
  • Shimadzu Corporation
  • Thermo Fisher Scientific Inc.
Product Code: MRR-434CCDA0516F

The Drug Discovery Market was valued at USD 62.38 billion in 2023 and is projected to grow to USD 71.12 billion in 2024, with a CAGR of 14.10%, reaching USD 157.13 billion by 2030.

A Comprehensive Introduction to the Evolution of Drug Discovery

KEY MARKET STATISTICS
Base Year [2023] USD 62.38 billion
Estimated Year [2024] USD 71.12 billion
Forecast Year [2030] USD 157.13 billion
CAGR (%) 14.10%

In recent years, the field of drug discovery has experienced an evolution that transcends traditional research paradigms. This transformation is driven by the convergence of scientific innovation, advanced technology, and an ever-changing regulatory and market environment. The industry's commitment to leveraging multidimensional insights and cutting-edge methodologies is now more critical than ever, as stakeholders strive to accelerate the journey from laboratory breakthroughs to viable therapeutic solutions.

Recent advancements in computational biology, automation of experimental protocols, and integration of data science have redefined how early-stage drug development is conducted. Organizations are increasingly investing in agile technologies that not only streamline high throughput screening processes but also enhance bioanalytical accuracy. These efforts have led to a more interconnected and responsive drug discovery lifecycle, where iterative learning and rapid prototyping are becoming the norm. In doing so, the sector positions itself to meet the growing demand for effective therapies while overcoming clinical challenges.

Furthermore, collaboration across academia, contract research organizations, and large pharmaceutical companies has set a collaborative tone for the industry. This heightened focus on interdisciplinary partnerships and cross-functional research underscores the transformative agenda of today's drug discovery landscape, laying the foundation for innovative therapeutic interventions that address complex disease profiles.

Transformative Shifts Redefining the Drug Discovery Landscape

The drug discovery arena is undergoing transformative shifts that have redefined its fundamental operational framework. A significant driver of this change is the rapid pace of technological advancement, which is turning once cumbersome cycles of research and development into streamlined, data-driven processes. As emerging technologies continue to integrate into traditional research workflows, the industry witnesses a seamless blend of scientific rigor with automation and computational modeling.

Advancements in artificial intelligence, enhanced imaging techniques, and robust data analytics are not only accelerating the identification of lead compounds but also enhancing the precision of clinical validation. This shift is further complemented by a global emphasis on personalized medicine, where tailored therapeutic approaches promise to address the heterogeneity of patient populations more effectively. Moreover, evolving regulatory frameworks are supporting faster approval processes without compromising safety, thereby cultivating an ecosystem that prizes innovation and agility.

These dynamic changes have fostered a climate where collaboration is paramount. Research institutions, biotech startups, and established pharmaceutical companies are pooling resources and expertise to tackle complex therapeutic challenges. Such broad-based integration of technology and science is setting the stage for a new era in drug discovery, where risk management and investment in state-of-the-art tools are pivotal to sustaining long-term competitive advantage.

Key Segmentation Insights Shaping the Future Research Arena

A meticulous examination of market segmentation reveals multiple layers of specialization within drug discovery. The industry is segmented based on drug type, where an in-depth study distinguishes between biologic drugs and small molecule drugs. This differentiation has profound implications on developmental pipelines, regulatory pathways, and market adoption strategies.

From a technology perspective, the landscape has embraced a range of sophisticated tools, including bioanalytical instruments, biochips, and bioinformatics, which form the backbone of modern research. Advanced techniques such as combinatorial chemistry, high throughput screening, and nanotechnology are also at the forefront, while pharmacogenomics is paving the way towards personalized care and targeted therapies. These technological segments contribute significant value by expediting drug development and ensuring precision in therapeutic targeting.

Further segmentation based on therapeutic areas underscores the targeted application of drug discovery efforts. Critical focus areas such as cardiovascular disease, digestive system diseases, infectious and immune system diseases, neurology, and oncology illustrate the diverse clinical settings that demand distinct research approaches. Finally, segmentation based on end users, which spans the academic community, research institutions, and contract research organizations, as well as large pharmaceutical companies, presents a layered view of market dynamics. This integration of segmentation insights empowers stakeholders to align strategies with specific market needs and clinical challenges, thereby maximizing research returns and clinical success.

Based on Drug Type, market is studied across Biologic Drugs and Small Molecule Drugs.

Based on Technology, market is studied across Bioanalytical Instruments, Biochips, Bioinformatics, Combinatorial Chemistry, High Throughput Screening, Nanotechnology, and Pharmacogenomics.

Based on Therapeutic Area, market is studied across Cardiovascular Disease, Digestive System Diseases, Infectious & Immune system Diseases, Neurology, and Oncology.

Based on End User, market is studied across Academics & Research Institutes, Contract Research Organizations, and Pharmaceutical Companies.

Regional Insights: A Global Perspective on Drug Discovery Innovation

The regional dynamics of drug discovery further enrich the analysis of this rapidly transforming industry. The Americas, with its robust infrastructural support for research and development, continues to lead in innovation. Intricate networks of academic institutions, biotech startups, and major pharmaceutical hubs create an environment ripe for transformative research and seamless commercialization of new therapies.

In Europe, Middle East, and Africa, a unique blend of regulatory precision and market demand fosters an ecosystem where breakthrough innovations reliably move from bench to bedside. This region's commitment to integrating advanced technological infrastructures with conventional research methodologies is notable, as it attracts significant global investment and collaborative efforts.

Across the Asia-Pacific region, rapid economic growth coupled with a surge in population-based studies and government-supported healthcare initiatives has accelerated advancements in drug discovery. In this diverse market, strategic partnerships and localized research initiatives play pivotal roles, driving faster adoption of cutting-edge technologies and broadening the scope of therapeutic research. These regional insights highlight a global breadth of innovation that reinforces the necessity for decentralized yet coordinated approaches to drug discovery.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Georgia, Illinois, Indiana, Michigan, New York, North Carolina, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Leading Company Insights in the Evolving Drug Discovery Fabric

Analyzing the contributions of key players in the market reveals the competitive intensity within the drug discovery space. Prominent companies such as Abbott Laboratories, Agilent Technologies, Inc., and Alacrita Holdings Limited are continually pushing the envelope by developing and integrating groundbreaking technologies. These organizations, alongside leaders like Alkem Laboratories Ltd and Amgen Inc., are setting benchmarks in drug development practices.

The influence of firms such as Astex Pharmaceuticals by Otsuka Pharmaceutical Co., Ltd., Astrazeneca PLC, and Atomwise, Inc. is evident in their relentless pursuit of innovative therapy development. Investments by BenevolentAI and Bio-Rad Laboratories, Inc. further highlight the drive towards harnessing artificial intelligence and data analytics to streamline discovery processes. Moreover, contributions from organizations like BioSymetrics Inc. and Charles River Laboratories International, Inc. have played a crucial role in refining experimental protocols and enhancing regulatory compliance.

Other notable companies such as Chembridge Corporation, Cloud Pharmaceuticals, Inc., Dalriada Drug Discovery, and Deciphera Pharmaceuticals, Inc. are strategically positioned to leverage emerging computational tools and novel research methodologies. The strategic alliances and technology integrations championed by Eli Lilly and Company, Evotec SE, Exscientia PLC, and F. Hoffmann-La Roche Ltd. underscore the importance of collaborative innovation. With further contributions from GENFIT SA, Incyte Corporation, International Business Machines Corporation, Intra-Cellular Therapies Inc., Kvantify, Lantern Pharma Inc., Merck KGaA, Microsoft Corporation, NVIDIA Corporation, PerkinElmer, Inc., Pharmacelera SL, and Piramal Group, the market is characterized by a rich interplay of scientific expertise and commercial acumen. Continuing this momentum, Recursion Pharmaceuticals, Inc., Sanofi S.A, Schrodinger, Inc., Shimadzu Corporation, and Thermo Fisher Scientific Inc. exemplify the dynamic and integrated nature of modern drug discovery endeavors.

The report delves into recent significant developments in the Drug Discovery Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Agilent Technologies, Inc., Alacrita Holdings Limited, Alkem Laboratories Ltd, Amgen Inc., Astex Pharmaceuticals by Otsuka Pharmaceutical Co., Ltd., Astrazeneca PLC, Atomwise, Inc., BenevolentAI, Bio-Rad Laboratories, Inc., BioSymetrics Inc., Charles River Laboratories International, Inc., Chembridge Corporation, Cloud Pharmaceuticals, Inc., Dalriada Drug Discovery, Deciphera Pharmaceuticals, Inc., Eli Lilly and Company, Evotec SE, Exscientia PLC, F. Hoffmann-La Roche Ltd., GENFIT SA, Incyte Corporation, International Business Machines Corporation, Intra-Cellular Therapies Inc., Kvantify, Lantern Pharma Inc., Merck KGaA, Microsoft Corporation, NVIDIA Corporation, PerkinElmer, Inc., Pharmacelera SL, Piramal Group, Recursion Pharmaceuticals, Inc., Sanofi S.A, Schrodinger, Inc., Shimadzu Corporation, and Thermo Fisher Scientific Inc.. Actionable Recommendations for Industry Leaders Navigating Change

Industry leaders should adopt a dynamic approach to address current challenges and sustain future growth. Embracing cross-disciplinary research efforts and investing in next-generation technologies is imperative for maintaining competitive advantage. Decision-makers are encouraged to prioritize initiatives that facilitate collaboration between academic research teams, contract research organizations, and established pharmaceutical companies, thereby creating a unified framework for agile innovation.

For organizations aiming to reduce time-to-market, integrating high throughput screening, advanced bioinformatics, and nanotechnology can result in more efficient identification of lead compounds. Investing in sophisticated bioanalytical instruments and leveraging combinatorial chemistry will further enhance the fidelity and speed of discovery processes. Such strategic investments not only optimize operational workflows but also foster a culture of innovation and continuous improvement.

It is advisable for stakeholders to closely monitor emerging regulatory trends and seek strategic partnerships that align with evolving market demands. Building robust digital infrastructures capable of managing large datasets and predictive analytics is a crucial step in driving success. Furthermore, tailoring therapeutic strategies to target specific clinical areas, such as oncology and neurology, will likely yield higher returns on investment. Ultimately, a cohesive strategy that blends technological adoption with market-specific insights will empower industry leaders to effectively navigate the rapidly evolving landscape.

Conclusion: Embracing Change for a Future-Ready Drug Discovery Ecosystem

The shifting paradigms within drug discovery underscore a transformative era marked by technological sophistication, strategic segmentation, and expansive global collaborations. In summary, the industry is reaping the benefits of advanced computational methods, dynamic regional investments, and the collective expertise of pioneering companies. These factors converge to create a fertile ground for innovation that is both economically and scientifically sustainable.

A robust drug discovery framework today is defined by its openness to disruptive technologies and cross-sectoral partnerships. As the market continues to evolve, stakeholders across the spectrum must continually reassess investment strategies while embracing integrated workflows that streamline the research and development process. The synthesis of advanced technological integrations with strategic market insights ensures that the drug discovery ecosystem is poised to deliver novel therapeutic solutions that address unmet clinical needs.

In essence, the future of drug discovery hinges on our ability to harness innovation, collaborate across traditional silos, and implement forward-thinking solutions that respond to the challenges of an increasingly complex global landscape. The journey ahead is one of both opportunity and responsibility, requiring all players to be agile, innovative, and collaborative in their pursuit of scientific excellence.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising R&D expenditure in the pharmaceutical & biopharmaceutical industry
      • 5.1.1.2. Increasing need to manage large data generated during preclinical studies
      • 5.1.1.3. Favorable government support for the development of drug discovery platforms
    • 5.1.2. Restraints
      • 5.1.2.1. Requirement of extensive capital for drug discovery and development
    • 5.1.3. Opportunities
      • 5.1.3.1. Emerging collaborations among companies to expand their drug discovery capabilities
      • 5.1.3.2. Technological advancements and innovations in drug discovery
      • 5.1.3.3. Use of AI cloud to create a streamlined and automated approach in drug discovery
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent norms for animal usage in drug discovery
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Drug Type: Growing need for small molecule drugs with branded and generic products
    • 5.2.2. Technology: Growing utilization of bioanalytical instruments and high throughput screening for initial drug discovery phases
    • 5.2.3. Therapeutic Area: Increasing need of drug discovery for the development of oncology drugs
    • 5.2.4. End User: Growing drug discovery use across pharmaceutical and biotechnology companies for developing new and improved drugs
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Drug Discovery Market, by Drug Type

  • 6.1. Introduction
  • 6.2. Biologic Drugs
  • 6.3. Small Molecule Drugs

7. Drug Discovery Market, by Technology

  • 7.1. Introduction
  • 7.2. Bioanalytical Instruments
  • 7.3. Biochips
  • 7.4. Bioinformatics
  • 7.5. Combinatorial Chemistry
  • 7.6. High Throughput Screening
  • 7.7. Nanotechnology
  • 7.8. Pharmacogenomics

8. Drug Discovery Market, by Therapeutic Area

  • 8.1. Introduction
  • 8.2. Cardiovascular Disease
  • 8.3. Digestive System Diseases
  • 8.4. Infectious & Immune system Diseases
  • 8.5. Neurology
  • 8.6. Oncology

9. Drug Discovery Market, by End User

  • 9.1. Introduction
  • 9.2. Academics & Research Institutes
  • 9.3. Contract Research Organizations
  • 9.4. Pharmaceutical Companies

10. Americas Drug Discovery Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Drug Discovery Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Drug Discovery Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Exscientia PLC partners with AWS to harness AI and cloud technology for accelerating drug discovery and reducing costs
    • 13.3.2. Enzene Biosciences launches new drug discovery division offering integrated services
    • 13.3.3. Emory University's Center for New Medicines accelerates drug discovery with advanced technology for improved patient outcomes and collaborative research.
    • 13.3.4. Oregon Therapeutics partners with Lantern Pharma to advance XCE853 development using RADR AI platform, targeting drug-resistant cancers
    • 13.3.5. Xaira Therapeutics launches with over USD 1 billion funding to revolutionize AI-driven drug discovery with innovative machine learning models
    • 13.3.6. bioXcelerate launches PleioGraph AI tool to revolutionize drug discovery, cutting costs and accelerating treatments by 100x
    • 13.3.7. UC Berkeley's Molecular Therapeutics Initiative (MTI) aims to accelerate breakthrough treatments for neurological, metabolic diseases, and cancer through interdisciplinary collaboration
    • 13.3.8. Danish quantum computing firm Kvantify unveils Kvantify Koffee to revolutionize drug discovery with expedited screening, cost reduction, and future-proof technology integration
    • 13.3.9. Washington University and Deerfield Management partner to launch VeritaScience, committing USD 130 million to advance drug discovery and development
    • 13.3.10. Arena BioWorks opens in Kendall Square with USD 500 million to accelerate drug discovery and market innovative medicines.
    • 13.3.11. Evommune and Accutar Biotechnology announce AI drug discovery collaboration
    • 13.3.12. IGC Pharma signs agreement to adopt AI solutions into drug discovery
    • 13.3.13. University of Tsukuba and Astellas Pharma Inc. confirm a strategic partnership
    • 13.3.14. Sosei and PharmEnable collaborate on another neurological drug
    • 13.3.15. Novo Nordisk and Evotec launch translational drug discovery accelerator
    • 13.3.16. Genesis raises USD 200 million for AI drug discovery research
  • 13.4. Strategy Analysis & Recommendation
    • 13.4.1. NVIDIA Corporation
    • 13.4.2. F. Hoffmann-La Roche Ltd.
    • 13.4.3. Exscientia PLC
    • 13.4.4. Alkem Laboratories Ltd

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Agilent Technologies, Inc.
  • 3. Alacrita Holdings Limited
  • 4. Alkem Laboratories Ltd
  • 5. Amgen Inc.
  • 6. Astex Pharmaceuticals by Otsuka Pharmaceutical Co., Ltd.
  • 7. Astrazeneca PLC
  • 8. Atomwise, Inc.
  • 9. BenevolentAI
  • 10. Bio-Rad Laboratories, Inc.
  • 11. BioSymetrics Inc.
  • 12. Charles River Laboratories International, Inc.
  • 13. Chembridge Corporation
  • 14. Cloud Pharmaceuticals, Inc.
  • 15. Dalriada Drug Discovery
  • 16. Deciphera Pharmaceuticals, Inc.
  • 17. Eli Lilly and Company
  • 18. Evotec SE
  • 19. Exscientia PLC
  • 20. F. Hoffmann-La Roche Ltd.
  • 21. GENFIT SA
  • 22. Incyte Corporation
  • 23. International Business Machines Corporation
  • 24. Intra-Cellular Therapies Inc.
  • 25. Kvantify
  • 26. Lantern Pharma Inc.
  • 27. Merck KGaA
  • 28. Microsoft Corporation
  • 29. NVIDIA Corporation
  • 30. PerkinElmer, Inc.
  • 31. Pharmacelera SL
  • 32. Piramal Group
  • 33. Recursion Pharmaceuticals, Inc.
  • 34. Sanofi S.A
  • 35. Schrodinger, Inc.
  • 36. Shimadzu Corporation
  • 37. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. DRUG DISCOVERY MARKET MULTI-CURRENCY
  • FIGURE 2. DRUG DISCOVERY MARKET MULTI-LANGUAGE
  • FIGURE 3. DRUG DISCOVERY MARKET RESEARCH PROCESS
  • FIGURE 4. DRUG DISCOVERY MARKET SIZE, 2023 VS 2030
  • FIGURE 5. GLOBAL DRUG DISCOVERY MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 6. GLOBAL DRUG DISCOVERY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL DRUG DISCOVERY MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL DRUG DISCOVERY MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. AMERICAS DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES DRUG DISCOVERY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 19. UNITED STATES DRUG DISCOVERY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. DRUG DISCOVERY MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 25. DRUG DISCOVERY MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. DRUG DISCOVERY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL DRUG DISCOVERY MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL DRUG DISCOVERY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. DRUG DISCOVERY MARKET DYNAMICS
  • TABLE 7. GLOBAL DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL DRUG DISCOVERY MARKET SIZE, BY BIOLOGIC DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL DRUG DISCOVERY MARKET SIZE, BY SMALL MOLECULE DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL DRUG DISCOVERY MARKET SIZE, BY BIOANALYTICAL INSTRUMENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL DRUG DISCOVERY MARKET SIZE, BY BIOCHIPS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL DRUG DISCOVERY MARKET SIZE, BY BIOINFORMATICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL DRUG DISCOVERY MARKET SIZE, BY COMBINATORIAL CHEMISTRY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL DRUG DISCOVERY MARKET SIZE, BY HIGH THROUGHPUT SCREENING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL DRUG DISCOVERY MARKET SIZE, BY NANOTECHNOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL DRUG DISCOVERY MARKET SIZE, BY PHARMACOGENOMICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL DRUG DISCOVERY MARKET SIZE, BY CARDIOVASCULAR DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL DRUG DISCOVERY MARKET SIZE, BY DIGESTIVE SYSTEM DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL DRUG DISCOVERY MARKET SIZE, BY INFECTIOUS & IMMUNE SYSTEM DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL DRUG DISCOVERY MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL DRUG DISCOVERY MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL DRUG DISCOVERY MARKET SIZE, BY ACADEMICS & RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL DRUG DISCOVERY MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL DRUG DISCOVERY MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. ARGENTINA DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 35. ARGENTINA DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 36. ARGENTINA DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 37. BRAZIL DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. BRAZIL DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 39. BRAZIL DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 40. BRAZIL DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 41. CANADA DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. CANADA DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 43. CANADA DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 44. CANADA DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 45. MEXICO DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. MEXICO DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 47. MEXICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 48. MEXICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 49. UNITED STATES DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. UNITED STATES DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 51. UNITED STATES DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 52. UNITED STATES DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 53. UNITED STATES DRUG DISCOVERY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 54. ASIA-PACIFIC DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. ASIA-PACIFIC DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 56. ASIA-PACIFIC DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 57. ASIA-PACIFIC DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 58. ASIA-PACIFIC DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 59. AUSTRALIA DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. AUSTRALIA DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 61. AUSTRALIA DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 62. AUSTRALIA DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 63. CHINA DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. CHINA DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 65. CHINA DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 66. CHINA DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 67. INDIA DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. INDIA DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 69. INDIA DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 70. INDIA DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 71. INDONESIA DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. INDONESIA DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 73. INDONESIA DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 74. INDONESIA DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 75. JAPAN DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. JAPAN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 77. JAPAN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 78. JAPAN DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 79. MALAYSIA DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. MALAYSIA DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 81. MALAYSIA DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 82. MALAYSIA DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 83. PHILIPPINES DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. PHILIPPINES DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 85. PHILIPPINES DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 86. PHILIPPINES DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 87. SINGAPORE DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. SINGAPORE DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 89. SINGAPORE DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 90. SINGAPORE DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 91. SOUTH KOREA DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. SOUTH KOREA DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 93. SOUTH KOREA DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 94. SOUTH KOREA DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 95. TAIWAN DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. TAIWAN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 97. TAIWAN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 98. TAIWAN DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 99. THAILAND DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. THAILAND DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 101. THAILAND DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 102. THAILAND DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 103. VIETNAM DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. VIETNAM DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 105. VIETNAM DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 106. VIETNAM DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 110. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 111. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 112. DENMARK DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. DENMARK DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 114. DENMARK DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 115. DENMARK DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 116. EGYPT DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. EGYPT DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 118. EGYPT DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 119. EGYPT DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 120. FINLAND DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. FINLAND DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 122. FINLAND DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 123. FINLAND DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 124. FRANCE DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. FRANCE DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 126. FRANCE DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 127. FRANCE DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 128. GERMANY DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. GERMANY DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 130. GERMANY DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 131. GERMANY DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 132. ISRAEL DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. ISRAEL DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 134. ISRAEL DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 135. ISRAEL DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 136. ITALY DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. ITALY DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 138. ITALY DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 139. ITALY DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 140. NETHERLANDS DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. NETHERLANDS DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 142. NETHERLANDS DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 143. NETHERLANDS DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 144. NIGERIA DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. NIGERIA DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 146. NIGERIA DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 147. NIGERIA DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 148. NORWAY DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 149. NORWAY DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 150. NORWAY DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 151. NORWAY DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 152. POLAND DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 153. POLAND DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 154. POLAND DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 155. POLAND DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 156. QATAR DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 157. QATAR DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 158. QATAR DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 159. QATAR DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 160. RUSSIA DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 161. RUSSIA DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 162. RUSSIA DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 163. RUSSIA DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 164. SAUDI ARABIA DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 165. SAUDI ARABIA DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 166. SAUDI ARABIA DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 167. SAUDI ARABIA DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 168. SOUTH AFRICA DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 169. SOUTH AFRICA DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 170. SOUTH AFRICA DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 171. SOUTH AFRICA DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 172. SPAIN DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 173. SPAIN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 174. SPAIN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 175. SPAIN DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 176. SWEDEN DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 177. SWEDEN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 178. SWEDEN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 179. SWEDEN DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 180. SWITZERLAND DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 181. SWITZERLAND DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 182. SWITZERLAND DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 183. SWITZERLAND DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 184. TURKEY DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 185. TURKEY DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 186. TURKEY DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 187. TURKEY DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED ARAB EMIRATES DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED ARAB EMIRATES DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED ARAB EMIRATES DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 191. UNITED ARAB EMIRATES DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 192. UNITED KINGDOM DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 193. UNITED KINGDOM DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 194. UNITED KINGDOM DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 195. UNITED KINGDOM DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 196. DRUG DISCOVERY MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 197. DRUG DISCOVERY MARKET, FPNV POSITIONING MATRIX, 2023